Detection of antibodies to anti-TNF agents in psoriatic patients

A preliminary study

E. Cozzani, M. Burlando, A. Parodi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Aim. The efficacy of anti-TNFα agents in psoriasis (Pso) has been established in different clinical trials and in every day practice. However, a portion of patients (non-responder patients) persists with active disease or relapses even during current biological therapy. In addition to this, the use of biologic agents can give adverse drug reactions. All these factors may be due to the immunogenicity of these new biological drugs. All the biological proteins, including fully human proteins, have the potential to induce immunogenicity which leads to the development of specific antidrug antibodies (ADAs). Methods. In a retrospective way, we studied ADAs, using ELISA test, in a group of 51 patients with moderate to severe Pso treated with anti TNF α drugs: 18 Etanercept (ETN), 15 infliximab (IFX) and 18 adalimumab (AdA). Results. Anti-IFX antibodies were positive in 13.3%, anti AdA in 16.6% while all the patients treated with ETN did not present ADAs. Our opinion is that it is important to verify non-responder patients due to neutralizing ADAs so that we can change the drug before patients get worse. Moreover, it is important to detect ADAs since positive patients are more likely to develop acute hypersensitivity reactions. The development of antimonoclonal specific IgGs may also lead to an effector mechanism involving complement activation and production of anaphylotoxins which determine side effects that can be, in some cases, very severe. ADAs can be responsible of the poor response to the drugs and can impact the safety profile of the drugs. Conclusion. We think that the detection of ADAs will be useful for the management of the drugs and the disease in all patients with psoriasis in treatment with anti biological drugs as a routine clinical practice.

Original languageEnglish
Pages (from-to)171-174
Number of pages4
JournalGiornale Italiano di Dermatologia e Venereologia
Volume148
Issue number2
Publication statusPublished - 2013

Fingerprint

Anti-Idiotypic Antibodies
Antibodies
Pharmaceutical Preparations
Psoriasis
Biological Therapy
Complement Activation
Biological Factors
Disease Management
Neutralizing Antibodies
Drug-Related Side Effects and Adverse Reactions
Hypersensitivity
Proteins
Enzyme-Linked Immunosorbent Assay
Clinical Trials
Safety
Recurrence

Keywords

  • Antibodies
  • Biological agents
  • Psoriasis

ASJC Scopus subject areas

  • Dermatology

Cite this

Detection of antibodies to anti-TNF agents in psoriatic patients : A preliminary study. / Cozzani, E.; Burlando, M.; Parodi, A.

In: Giornale Italiano di Dermatologia e Venereologia, Vol. 148, No. 2, 2013, p. 171-174.

Research output: Contribution to journalArticle

@article{649626c8725a4e7cbef04f2641e111c7,
title = "Detection of antibodies to anti-TNF agents in psoriatic patients: A preliminary study",
abstract = "Aim. The efficacy of anti-TNFα agents in psoriasis (Pso) has been established in different clinical trials and in every day practice. However, a portion of patients (non-responder patients) persists with active disease or relapses even during current biological therapy. In addition to this, the use of biologic agents can give adverse drug reactions. All these factors may be due to the immunogenicity of these new biological drugs. All the biological proteins, including fully human proteins, have the potential to induce immunogenicity which leads to the development of specific antidrug antibodies (ADAs). Methods. In a retrospective way, we studied ADAs, using ELISA test, in a group of 51 patients with moderate to severe Pso treated with anti TNF α drugs: 18 Etanercept (ETN), 15 infliximab (IFX) and 18 adalimumab (AdA). Results. Anti-IFX antibodies were positive in 13.3{\%}, anti AdA in 16.6{\%} while all the patients treated with ETN did not present ADAs. Our opinion is that it is important to verify non-responder patients due to neutralizing ADAs so that we can change the drug before patients get worse. Moreover, it is important to detect ADAs since positive patients are more likely to develop acute hypersensitivity reactions. The development of antimonoclonal specific IgGs may also lead to an effector mechanism involving complement activation and production of anaphylotoxins which determine side effects that can be, in some cases, very severe. ADAs can be responsible of the poor response to the drugs and can impact the safety profile of the drugs. Conclusion. We think that the detection of ADAs will be useful for the management of the drugs and the disease in all patients with psoriasis in treatment with anti biological drugs as a routine clinical practice.",
keywords = "Antibodies, Biological agents, Psoriasis",
author = "E. Cozzani and M. Burlando and A. Parodi",
year = "2013",
language = "English",
volume = "148",
pages = "171--174",
journal = "Minerva dermatologica",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Detection of antibodies to anti-TNF agents in psoriatic patients

T2 - A preliminary study

AU - Cozzani, E.

AU - Burlando, M.

AU - Parodi, A.

PY - 2013

Y1 - 2013

N2 - Aim. The efficacy of anti-TNFα agents in psoriasis (Pso) has been established in different clinical trials and in every day practice. However, a portion of patients (non-responder patients) persists with active disease or relapses even during current biological therapy. In addition to this, the use of biologic agents can give adverse drug reactions. All these factors may be due to the immunogenicity of these new biological drugs. All the biological proteins, including fully human proteins, have the potential to induce immunogenicity which leads to the development of specific antidrug antibodies (ADAs). Methods. In a retrospective way, we studied ADAs, using ELISA test, in a group of 51 patients with moderate to severe Pso treated with anti TNF α drugs: 18 Etanercept (ETN), 15 infliximab (IFX) and 18 adalimumab (AdA). Results. Anti-IFX antibodies were positive in 13.3%, anti AdA in 16.6% while all the patients treated with ETN did not present ADAs. Our opinion is that it is important to verify non-responder patients due to neutralizing ADAs so that we can change the drug before patients get worse. Moreover, it is important to detect ADAs since positive patients are more likely to develop acute hypersensitivity reactions. The development of antimonoclonal specific IgGs may also lead to an effector mechanism involving complement activation and production of anaphylotoxins which determine side effects that can be, in some cases, very severe. ADAs can be responsible of the poor response to the drugs and can impact the safety profile of the drugs. Conclusion. We think that the detection of ADAs will be useful for the management of the drugs and the disease in all patients with psoriasis in treatment with anti biological drugs as a routine clinical practice.

AB - Aim. The efficacy of anti-TNFα agents in psoriasis (Pso) has been established in different clinical trials and in every day practice. However, a portion of patients (non-responder patients) persists with active disease or relapses even during current biological therapy. In addition to this, the use of biologic agents can give adverse drug reactions. All these factors may be due to the immunogenicity of these new biological drugs. All the biological proteins, including fully human proteins, have the potential to induce immunogenicity which leads to the development of specific antidrug antibodies (ADAs). Methods. In a retrospective way, we studied ADAs, using ELISA test, in a group of 51 patients with moderate to severe Pso treated with anti TNF α drugs: 18 Etanercept (ETN), 15 infliximab (IFX) and 18 adalimumab (AdA). Results. Anti-IFX antibodies were positive in 13.3%, anti AdA in 16.6% while all the patients treated with ETN did not present ADAs. Our opinion is that it is important to verify non-responder patients due to neutralizing ADAs so that we can change the drug before patients get worse. Moreover, it is important to detect ADAs since positive patients are more likely to develop acute hypersensitivity reactions. The development of antimonoclonal specific IgGs may also lead to an effector mechanism involving complement activation and production of anaphylotoxins which determine side effects that can be, in some cases, very severe. ADAs can be responsible of the poor response to the drugs and can impact the safety profile of the drugs. Conclusion. We think that the detection of ADAs will be useful for the management of the drugs and the disease in all patients with psoriasis in treatment with anti biological drugs as a routine clinical practice.

KW - Antibodies

KW - Biological agents

KW - Psoriasis

UR - http://www.scopus.com/inward/record.url?scp=84879021925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879021925&partnerID=8YFLogxK

M3 - Article

VL - 148

SP - 171

EP - 174

JO - Minerva dermatologica

JF - Minerva dermatologica

SN - 0392-0488

IS - 2

ER -